Trial Profile
A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (RIX 4414; Rotarix) in healthy infants
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs RIX 4414 (Primary)
- Indications Gastroenteritis; Rotavirus infections
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 15 Feb 2020 Results of pooled analysis from nine studies including this study published in the Journal of Infectious Diseases.
- 16 Feb 2007 New trial record.